Recent progress indicates a considerably improved mechanistic understanding of CAR T cell biology and delivers important insights into why some patients achieve durable remissions and others do not. In addition, although most success has been achieved in the context of CAR T cells targeted to B cell tumor antigens, namely CD19 and BCMA, we are seeing promising clinical trial outcomes for solid tumor malignancies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies
Journal of Biomedical Science Open Access 12 January 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Brentjens, R. J. et al. Sci. Transl. Med. 5, 177ra138 (2013).
Locke, F. L. et al. N. Engl. J. Med. 386, 640–654 (2022).
Kamdar, M. et al. Lancet 399, 2294–2308 (2022).
Jain, M. D. Mol. Ther. 30, 14–16 (2022).
Melenhorst, J. J. et al. Nature 602, 503–509 (2022).
Haradhvala, N. J. et al. Nat. Med. 28, 1848–1859 (2022).
Good, Z. et al. Nat. Med. 28, 1860–1871 (2022).
Lee, J. C. et al. Cancer Res. 71, 2871–2881 (2011).
Scholler, N. et al. Nat. Med. 28, 1872–1882 (2022).
Jain, M. D. et al. Blood 137, 2621–2633 (2021).
Faramand, R. et al. Clin. Cancer Res. 26, 4823–4831 (2020).
Jain, M. D. et al. Blood 140, 491–503 (2022).
Mailankody, S. et al. N. Engl. J. Med. 387, 1196–1206 (2022).
Qi, C. et al. Nat. Med. 28, 1189–1198 (2022).
Narayan, V. et al. Nat. Med. 28, 724–734 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.L.D. has equity or options to purchase equity in Bellicum, Precision Biosciences and Adicet. M.L.D. has received licensing revenue from CRISPR and Atara Biotherapeutics. M.L.D. has received fees from Adicet, Syncopation, Synthekine and Bellicum. R.J.B. has licensed intellectual property to and collect royalties from Bristol Myers Squibb (BMS), Caribou and Sanofi. R.J.B. received research funding from BMS. R.J.B. is a consultant to BMS, Atara Biotherapeutics, Coimmune and Triumvira, and was a consultant for Gracell Biotechnologies, but ended employment in the past 24 months. R.J.B. is a member of the scientific advisory board for CoImmune and Triumvira.
Rights and permissions
About this article
Cite this article
Davila, M.L., Brentjens, R.J. CAR T cell therapy: looking back and looking forward. Nat Cancer 3, 1418–1419 (2022). https://doi.org/10.1038/s43018-022-00484-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00484-w
This article is cited by
-
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies
Journal of Biomedical Science (2024)
-
Towards targeting transposable elements for cancer therapy
Nature Reviews Cancer (2024)